Abstract:

Abstract:Objective To observe the influence of azelnidipine  in clinical efficacy and serum levels of high sensitive Ｃ-reactive　protein (hs-CRP),superoxide dismutase(SOD) and 6-ketone prostaglandins 　F1α　 (6-keto-PGF1α) in  patients with hypertension and to clarify  the effectiveness of azelnidipine on realeasing blood pressure and suppressing the development of atherosclerosis (AS).Methods 48 patients with hypertension were randomly divided into azelnidipine group(n=24) and amlodipine besylate group(n=24).After two-week drug clearance，the patients in two group receieved azelnidipine (8-16 mg/d
) or amlodipine besylate (5-10 mg/d) for 8 weeks.The blood pressure and the serum levels of hs-CRP,SOD and 6-keto-PGF1α before and after treatment were detected and compared. Results The systotlic blood pressure(SBP) and diastolic blood pressure(DBP) of the patients in two groups were significantly decreased,the effective rates in azelnidipine group and amlodipine besylate group were 87.5 and 91.7%，there was no significant difference between two groups(P>0.05).There was no significant difference of blood biochemisal indexes of the patients between two groups before and after treatment(P>0.05).There were no significant differences of plasma hs-CRP,SOD,and 6-keto-PGF1α of the patients between two groups before and after treatment(P>0.05).Compared with before treatment,the hs-CRP levels of the patients in two groups were significantly decreased(P<0.05),the SOD levels were increased(P<0.05);the 6-keto-PGF1α level of the patients in azelnidipine group after treatment was increased(P<0.05),but there was no change in amlodipine besylate group(P>0.05).Conclusion Azelnidipine can significantly decrease the blood pressure. It inhibit the formation and development of atherosclerosis.

Key words: hypertension, azelnidipine, amlodipine besylate, atherosclerosis；hypersensitive C-reactive protein;superoxide dismutase, 6-keto-PGF1α